Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States

Authors: Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, Dalal M Abstract Introduction: In this real-world study, the incidence of cardiovascular events (CV) including major adverse cardiac events (MACE), arterial occlusive events (AOE), and...

Content Gate Template

Real-world Data (RWD) Insights in Precision Medicine - Oncology  This PDF download details advances in precision oncology treatment and the impact that STATinMED's RWD Insights Data has in evaluating patient outcomes, reducing cost of care, and the value of testing...